-
Uncategorized1 month ago
Samsung Biologics workers begin five-day strike over wage disputes
Samsung Biologics workers begin five-day strike over wage disputes
-
Uncategorized1 month ago
Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China
Cue Biopharma announced a reboot Thursday afternoon, bringing in notable biotech executive Shao-Lee Lin as well as a new allergy asset developed in Taiwan and mainland...
-
Uncategorized1 month ago
Novartis unveils North Carolina API plant as final piece of $23B US expansion
The new plant will give Novartis end-to-end capabilities centered on North Carolina, where it plans to have five facilities across three sites.
-
Uncategorized1 month agoBristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi...
-
Uncategorized1 month ago
Moderna beats revenue expectations with $389M, but litigation dogs earnings
CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity.
-
Uncategorized1 month agoSTAT+: Axsome wins FDA nod for Alzheimer’s agitation
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The FDA named Katherine Szarama...
-
Uncategorized1 month ago
The missing link in treating cancer
Eden Ben, CEO of Amorphical, and Dr Yigal Blum, CTO of Amorphical, argue that targeting the hostile tumour microenvironment is the key to effectively treating this...
-
Uncategorized1 month agoPFAS is still in some infant formula
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Too much news yesterday, so here’s a link...
-
Uncategorized1 month ago
Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration
Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial...
-
Uncategorized1 month ago
Amgen positions MariTide as potential ‘best monthly’ obesity drug
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own investigational obesity asset MariTide, which could...
